Belite Bio Inc., a clinical-stage drug development company focused on therapies for degenerative retinal diseases, announced a corporate reorganization involving the transfer of its exclusive license agreement with Columbia University. The company's wholly owned subsidiary, Belite Bio (HK) Limited, has assigned its rights and obligations under the agreement to Belite Bio (Swiss) AG, another wholly owned subsidiary. This move is intended to optimize the company's tax structure for potential future sub-licensing or collaborations. The assignment has received the necessary consent from Columbia University and will not affect Belite Bio's business or operations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.